At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jun 22, 2026 at 07:00 ET
Regeneron announced FDA and EMA acceptance of regulatory applications for cemdisiran, an investigational siRNA therapy for generalized myasthenia gravis (gMG). The FDA granted Priority Review with a target action date in November 2026, and the EMA decision is expected in H2 2027. This is a significant pipeline catalyst for Regeneron, as cemdisiran could become the first siRNA approved for gMG with a convenient subcutaneous dosing schedule four times a year.
- FDA accepted NDA for cemdisiran under Priority Review; target action date November 2026.
- EMA accepted regulatory application; decision anticipated H2 2027.
- Cemdisiran is an investigational siRNA targeting C5 for anti-AChR antibody-positive gMG.
- Phase 3 NIMBLE trial data published in The Lancet and presented at AAN 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access